TG 4010

Drug Profile

TG 4010

Alternative Names: Cancer vaccine - Transgene; MVA-MUC1-IL2; TG-4010

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transgene
  • Developer Bristol-Myers Squibb; Transgene; University of California, Davis
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Interleukin 12 stimulants; Mucin 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Suspended Prostate cancer; Renal cell carcinoma
  • Discontinued Breast cancer

Most Recent Events

  • 23 Jan 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in Denmark (SC) (EudraCT2016-005115-41)
  • 16 Jan 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (SC) (NCT03353675)
  • 16 Jan 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in France, Belgium (SC) after January 2018 (NCT03353675)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top